文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1 挽救治疗大型随机试验的长期结局:ACTG A5241(OPTIONS)96 周结果

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS).
PubMed 文献 · J Infect Dis · 2020-01-01

OPTIONS 试验 96 周结果显示,在优化方案累计活性>2 个活性药物时,挽救治疗可安全省略 NRTIs,不影响疗效持久性;高耐药组多数仍可实现病毒学抑制。

要点

  • 优化方案累计活性>2 时,省略 NRTIs 不降低 96 周病毒学抑制率。
  • 年轻和启用新抗逆转录病毒药物较少者病毒学失败风险更高。
  • 即使耐药广泛,多数患者仍可达 HIV-1 RNA<200 copies/mL。

核心结论

  • 只要新方案累计活性>2 个活性药物,HIV-1 挽救治疗可安全省略 NRTIs,不损害疗效或应答持久性。
  • 年轻者和接受较少新抗逆转录病毒药物者需仔细监测。
  • 即使耐药更广泛,多数人仍可实现病毒学抑制。

研究设计与样本

  • 随机试验将病毒学失败且预期抗逆转录病毒敏感者随机分为省略或添加 NRTIs 组,另设高耐药组接受含 NRTIs 的优化方案。

主要发现

  • 第 96 周,省略 NRTIs 组 70%、添加 NRTIs 组 65% 的 360 名参与者 HIV-1 RNA<200 copies/mL。
  • 第 48 周后病毒学失败不常见。
  • 高耐药组第 96 周 53% 参与者 HIV-1 RNA<200 copies/mL。

关键数值与推荐

  • 省略 NRTIs 适用条件:优化方案累计活性>2 个活性抗逆转录病毒药物。
  • 病毒学抑制阈值:HIV-1 RNA<200 copies/mL。

临床怎么用

  • 对累计活性>2 个活性药物的挽救方案,可考虑省略 NRTIs 以简化治疗。
  • 对年轻患者和启用新药较少者加强病毒学监测。

局限性

  • 高耐药组非随机对照,长期耐久性在更广泛耐药人群中仍需进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain. METHODS: Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an optimized regimen including NRTIs. RESULTS: At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96. CONCLUSIONS: HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression. CLINICAL TRIALS REGISTRATION: NCT00537394.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gandhi RT, Tashima KT, Smeaton LM, et al. Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS). J Infect Dis. 2020. PMID: 31135883. doi:10.1093/infdis/jiz281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。